G Protein-Coupled Estrogen Receptor-Mediated Anti-Inflammatory and Mucosal Healing Activity of a Trimethylpyridinol Analogue in Inflammatory Bowel Disease
- Authors
- Awasthi, Bhuwan Prasad; Chaudhary, Prakash; Lim, Dongchul; Yadav, Kiran; Lee, Iyn-Hyang; Banskota, Suhrid; Chaudhary, Chhabi Lal; Karmacharya, Ujjwala; Lee, Jiwoo; Im, So Myoung; Nam, Yeonju; Eun, Ji Won; Lee, Sungeun; Lee, Ji-Min; Kim, Eun Soo; Ryou, Chongsuk; Kim, Tae Hun; Park, Hee Dong; Kim, Jung-Ae; Nam, Tae-gyu; Jeong, Byeong-Seon
- Issue Date
- Jun-2024
- Publisher
- American Chemical Society
- Citation
- Journal of Medicinal Chemistry, pp 1 - 21
- Pages
- 21
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of Medicinal Chemistry
- Start Page
- 1
- End Page
- 21
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/119852
- DOI
- 10.1021/acs.jmedchem.3c02458
- ISSN
- 0022-2623
1520-4804
- Abstract
- Inflammatory bowel disease (IBD) is characterized by abnormal immune responses, including elevated proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF alpha) and interleukin-6 (IL-6) in the gastrointestinal (GI) tract. This study presents the synthesis and anti-inflammatory evaluation of 2,4,5-trimethylpyridin-3-ol analogues, which exhibit dual inhibition of TNF alpha- and IL-6-induced inflammation. Analysis using in silico methods, including 3D shape-based target identification, modeling, and docking, identified G protein-coupled estrogen receptor 1 (GPER) as the molecular target for the most effective analogue, 6-26, which exhibits remarkable efficacy in ameliorating inflammation and restoring colonic mucosal integrity. This was further validated by surface plasmon resonance (SPR) assay results, which showed direct binding to GPER, and by the results showing that GPER knockdown abolished the inhibitory effects of 6-26 on TNF alpha and IL-6 actions. Notably, 6-26 displayed no cytotoxicity, unlike G1 and G15, a well-known GPER agonist and an antagonist, respectively, which induced necroptosis independently of GPER. These findings suggest that the GPER-selective compound 6-26 holds promise as a therapeutic candidate for IBD.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/119852)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.